Amicus Therapeutics Inc., a leading global biotechnology company

Amicus Therapeutics Inc. is an American biopharmaceutical company located in Cranbury, New Jersey. The firm deals with the development of advanced therapy drugs. The company chains of products are developed to treat rare kind of devastating human genetic diseases. Its star product includes migalastat. This a drug that is expected to treat Fabry disease patient based on their genetic diagnosis. Another medicine is SD-101, at therapy drug for Epidermolysis Bullosa (EB).


Amicus Therapeutics Inc. was founded in February 2002 by John F. Crowley, an American entrepreneur, and biotechnology executive. Before 2007 a variety of venture capital firms funded the company. These firms included Canaan Partners, Radius Venture and New Enterprise Associates. In the year 2007 Amicus Therapeutics Inc. was quoted in form of FOLD under the NASDAQ


Presently, the company has a direct and personal relationship with their patient. The company acts with integrity to comply with the set measures of safety and professionalism (WeeklyOpinion). The key characteristics of the company’s investments are: the disease must be rare and have a devastating disorder. Also, the technology invested in has the possibility of being the best. Lastly, for the benefit of the patient, a meaningful clinical data must be provided.


The company leadership


Mr. Crowley is the current Chief Executive Officer since 2005. Also, he is the chairman of the board from 2010, a post that was held by Donald Hayden, Jr who remains as the lead independent director. Mr. Crowley is a B.S in Foreign Services graduate from Georgetown University. He is also a holder of M.B.A from Harvard University.


Mr. Bradley Campbell is the company’s president and chief operating officer. Harvard Business School alumnus has 15-year experience in the area of Orphan Drug. Also, he graduated from Duke University with B.A. in Public Policy. Currently, Mr. Bradley is the one responsible for designing, strategizing and commercializing of the migalastat drug. Furthermore, his role in the company involves global marketing, technical operations, and program management functions.


Amicus Therapeutics chief financial officer is Chip Baird. Mr. Chip responsibility include in the area of human resource, project and facilities management, finance, and public relation. Baird is a Georgetown University graduate with B.S. Foreign service and a holder of M.B.A in finance.

More about Amicus Therapeutics at